Ursodeoxycholic acid

Generic Name
Ursodeoxycholic acid
Brand Names
Reltone, Urso, Urso Forte
Drug Type
Small Molecule
Chemical Formula
C24H40O4
CAS Number
128-13-2
Unique Ingredient Identifier
724L30Y2QR
Background

Ursodeoxycholic acid (UDCA), also known as ursodiol, is a naturally-occurring bile acid that constitutes a minor fraction of the human bile acid pool. UDCA has been used to treat liver disease for decades: its first use in traditional medicine dates back more than a hundred years. UDCA was first characterized in the bile of the Chinese black bear and is form...

Indication

Ursodeoxycholic acid is indicated for the treatment of patients with primary biliary cholangitis.

It is used for the short-term treatment of radiolucent, noncalcified gallbladder stones in patients selected for elective cholecystectomy. It is also used to prevent gallstone formation in obese patients experiencing rapid weight loss.

Associated Conditions
Gallstones, Primary Biliary Cholangitis
Associated Therapies
-
Clinical Trials
Related News

A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis

First Posted Date
2021-02-12
Last Posted Date
2021-02-12
Lead Sponsor
Instituto Mexicano del Seguro Social
Target Recruit Count
11
Registration Number
NCT04751188
Locations
🇲🇽

Instituto Mexicano de Seguro Social, Puebla, Mexico

Clinical Research of UCDA Reducing Medication Regimen in Stable PBC

Phase 4
Recruiting
Conditions
Primary Biliary Cholangitis
Interventions
Drug: ursodeoxycholic acid
First Posted Date
2020-12-02
Last Posted Date
2022-05-04
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
90
Registration Number
NCT04650243
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II

First Posted Date
2020-11-05
Last Posted Date
2021-03-22
Lead Sponsor
West China Hospital
Target Recruit Count
90
Registration Number
NCT04617561
Locations
🇨🇳

Division of Gastroenterology & Hepatology,West China Hospital,Sichuan University, Chengdu, Sichuan, China

Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children

First Posted Date
2020-09-09
Last Posted Date
2023-02-24
Lead Sponsor
University of Oxford
Target Recruit Count
400
Registration Number
NCT04542473
Locations
🇺🇬

Mulago Hospital, Kampala, Uganda

🇲🇼

Queen Elizabeth Central Hospital, Blantyre, Malawi

🇰🇪

KEMRI WT Clinical Trials Facility, Kilifi, Kenya

and more 1 locations

Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus

First Posted Date
2020-05-29
Last Posted Date
2022-08-19
Lead Sponsor
King's College London
Target Recruit Count
158
Registration Number
NCT04407650
Locations
🇬🇧

Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis

First Posted Date
2019-09-03
Last Posted Date
2023-06-07
Lead Sponsor
University of Leipzig
Target Recruit Count
1200
Registration Number
NCT04076527
Locations
🇩🇪

Charité-Campus Virchow-Klinikum, Berlin, Germany

🇩🇪

University Hospital Aachen, Aachen, Germany

🇩🇪

Charité - Campus Benjamin Franklin, Berlin, Germany

and more 41 locations

A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)

First Posted Date
2018-09-19
Last Posted Date
2021-02-15
Lead Sponsor
HighTide Biopharma Pty Ltd
Registration Number
NCT03678480

Clinical Trial on the Effect of the Sublimated Mare Milk Supplement on Primary Biliary Cholangitis

First Posted Date
2018-09-11
Last Posted Date
2021-01-26
Lead Sponsor
National Scientific Medical Center, Kazakhstan
Target Recruit Count
40
Registration Number
NCT03665519
Locations
🇰🇿

National Research Medical Center, Astana, Kazakhstan

Therapeutic And Dietary Effects Of The Sublimated Mare's Milk Supplement In Patients With Non-Alcoholic Steatohepatitis

First Posted Date
2018-09-10
Last Posted Date
2021-02-05
Lead Sponsor
Medical Centre Hospital of the President's Affairs Administration, Republic of Kazakhstan
Target Recruit Count
80
Registration Number
NCT03664596
Locations
🇰🇿

Medical Centre Hospital of the President's Affairs Administration, Astana, Kazakhstan

Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR

First Posted Date
2018-09-06
Last Posted Date
2018-11-27
Lead Sponsor
Zagazig University
Target Recruit Count
400
Registration Number
NCT03659058
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy